Reneuron eyes a partner with new stem cell data
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
Sanbio brings its Japanese retail fans down to earth
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
Deal hopes revive Reneuron
After years in the wilderness, the UK cell therapy specialist Reneuron could be about to seal a deal with a big US player.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.